Transcriptomic screening and in vitro validation suggest PENK involvement in mitochondrial quality-control dysregulation in diabetes-associated myocardial injury
Transcriptomisches Screening und in-vitro-Validierung deuten auf eine PENK-Beteiligung an der Dysregulation der mitochondrialen Qualitätskontrolle bei diabetesassoziierter Myokardschädigung hin
Frontiers in Cardiovascular Medicine · 09.11.2026 · 13
DOI: 10.3389/fcvm.2026.1970128 ↗Auf einen Blick
In Transkriptomdaten und in AC16-Kardiomyozyten war PENK mit hochglukosebedingter Zellschädigung und mitochondrialer Dysfunktion verbunden. PENK-Silencing verbesserte diese Parameter.
Fragestellung
Welche MQC-assoziierten Kandidatengene sind mit diabetesassoziierter Myokardschädigung verbunden, und welche funktionelle Rolle hat PENK unter Hochglukosebedingungen?
Methode
Differenzielle Expressionsanalyse, angereicherte MQC-assoziierte Signalwege und WGCNA in GSE4745; Priorisierung mit Score und Prüfung in GSE5606, GSE6880 und GSE197999. Funktionelle Tests in hochglukosebehandelten AC16-Kardiomyozyten mit zwei siRNAs gegen PENK.
Ergebnisse
192 differentiell exprimierte Gene, darunter 58 MQC-assoziierte Gene. PENK war in diabetischen Myokardproben erhöht. Unter Hochglukose verbesserte PENK-Knockdown die Zellviabilität, senkte cleaved caspase-3 und mitochondriales Superoxid und erhöhte das JC-1 rot/grün-Verhältnis.
Schlussfolgerung der Autor:innen
Die Studie identifiziert PENK als MQC-assoziierten Kandidaten bei hochglukoseinduzierter Kardiomyozytenschädigung. PENK-Suppression verringerte die Zellschädigung und verbesserte mitochondriale Funktionsphänotypen unter hyperglykämischem Stress.
Kernaussagen
- PENK war in diabetischen Myokardproben und unter Hochglukose erhöht.
- PENK-Knockdown verbesserte Zellviabilität und mitochondriale Parameter.
- Die Befunde wurden mit zwei unabhängigen siRNAs bestätigt.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 09.11.2026. Verfasst von Zheng Zuo und 8 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Mitochondrial dysfunction and dysregulated mitochondrial quality control (MQC) contribute to diabetes-associated myocardial injury. However, the potential involvement of proenkephalin (PENK) in cardiomyocyte injury and mitochondrial dysfunction under hyperglycemic conditions remains poorly understood. This study aimed to identify MQC-associated candidate genes and investigate the functional relevance of PENK in high-glucose-induced cardiomyocyte injury.
Methods
GSE4745 was used as the discovery cohort for differential expression analysis, MQC-related pathway enrichment, and weighted gene co-expression network analysis (WGCNA). Candidate genes were prioritized using an integrated discovery-based scoring approach and further evaluated in three supportive GEO cohorts (GSE5606, GSE6880, and GSE197999). PENK expression and function were investigated in high-glucose-treated AC16 cardiomyocytes. Two independent PENK-targeting siRNAs were used to assess cell viability, apoptosis-associated protein expression, mitochondrial superoxide-related fluorescence, and mitochondrial membrane potential. MQC-associated protein expression was also examined by Western blotting.
Results
Transcriptomic analysis identified 192 differentially expressed genes, including 58 MQC-related genes, and revealed alterations in fatty-acid oxidation, mitochondrial protein import, and mitophagy/autophagy-associated transcriptional programs. PENK emerged as a high-ranking candidate and exhibited increased expression in diabetic myocardial samples, with concordant expression changes across the supportive cohorts. High-glucose exposure increased PENK expression and impaired AC16 cell viability and mitochondrial function. PENK knockdown significantly improved cell viability, reduced cleaved caspase-3 expression and mitochondrial superoxide-related fluorescence, and increased the JC-1 red/green fluorescence ratio. These changes were accompanied by reduced PINK1, Parkin, and DRP1 protein abundance and increased MFN2 expression. Importantly, an independent si-PENK #2 experiment reproduced the improvements in cellular injury and mitochondrial phenotypes observed with si-PENK #1.
Conclusions
This study identifies PENK as an MQC-associated candidate involved in high-glucose-induced cardiomyocyte injury. Consistent findings from two independent PENK-targeting siRNAs indicate that PENK suppression attenuates cellular injury and improves mitochondrial functional phenotypes under hyperglycemic stress. These findings provide experimental evidence supporting the potential relevance of PENK to mitochondrial dysfunction in diabetes-associated myocardial injury.
Zitieren
APA
Zuo, Z., He, B., Ming, Y., Liu, J., Zhu, K., Lai, H., Wang, C., Li, J., & Zhai, J. (2026). Transcriptomic screening and in vitro validation suggest PENK involvement in mitochondrial quality-control dysregulation in diabetes-associated myocardial injury. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1970128
Vancouver
Zuo Z, He B, Ming Y, Liu J, Zhu K, Lai H, et al. Transcriptomic screening and in vitro validation suggest PENK involvement in mitochondrial quality-control dysregulation in diabetes-associated myocardial injury. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1970128
BibTeX
@article{Zuo2026,
author = {Zuo, Zheng and He, Beibei and Ming, Yang and Liu, Jiaxing and Zhu, Kai and Lai, Hao and Wang, Chunsheng and Li, Jun and Zhai, Junyu},
title = {Transcriptomic screening and in vitro validation suggest PENK involvement in mitochondrial quality-control dysregulation in diabetes-associated myocardial injury},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1970128}
}
EUVIMED